Sweden's iZafe Group Q1 operating loss widens as investment spending rises

iZafe AB

28/04/2026 07:40

Overview

Sweden life science firm's Q1 net sales rose yr/yr, driven by recurring license revenues

Operating loss widened as company invested in sales and consolidated Dutch operations

Company completed SEK 19.8 mln share issue to fund expansion and secured new framework agreements

Outlook

iZafe Group maintains full-year 2026 ARR forecast at SEK 22.5 mln

Company expects accelerated recurring revenue growth as new contracts begin to impact results

Company says pace of call-offs and revenue conversion from agreements remains uncertain

Result Drivers

RECURRING REVENUE BASE - Q1 net sales consisted entirely of recurring license revenues, with no hardware sales, reflecting the company's business model

CONTRACTS NOT YET CONTRIBUTING - Company said new framework agreements and contracts secured in Q1 had not yet impacted revenue, with effects expected in coming quarters

HIGHER COSTS FROM INVESTMENT - Increased investments in sales, organization, and international operations, including new hires, led to higher costs and a wider operating loss

Company press release: ID:nMFN2z4KfB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 2.42 mln
Q1 Adjusted EPS
-SEK 0.02
Q1 Operating Profit
-SEK 8.30 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)